Parexel opens early phase unit in South Africa
Parexel, a global biopharmaceutical services provider headquartered in the US, has expanded its capabilities with the opening of an early phase unit in Port Elizabeth, South Africa.
Parexel, a global biopharmaceutical services provider headquartered in the US, has expanded its capabilities with the opening of an early phase unit in Port Elizabeth, South Africa.
The Port Elizabeth unit has added more than 40 beds to Parexel's global early phase capacity of more than 580 beds, which the company claims is among the largest in the world. The core focus of the unit is on early phase studies in patients, from first in man to proof of concept studies.
Parexel already has two early phase units in South Africa, in Bloemfontein and George, which have conducted early phase patient studies by combining Phase I expertise with patient recruitment.
The company now has early phase units in four continents - Baltimore and Los Angeles in the US; London in the UK; Berlin in Germany; and Port Elizabeth, Bloemfontein and George in South Africa.
The early phase unit in Port Elizabeth will serve as one of the units in the Parexel SuperSites network, which provides high enrolment potential for clinical studies, drawing on patient recruitment specialists and relationships with local healthcare professionals. The company's call centre and database capabilities allow for a high number of patients to be recruited in a rapid timeframe.
"The opening of our early phase unit in Port Elizabeth represents Parexel's further commitment to offering rapid recruitment solutions to our clients," said Michelle Middle, corporate vice president and worldwide head of early phase at Parexel.
